Thymosin Alpha-1 vs Thymosin Beta-4+

Thymosin Alpha-1 vs Thymosin Beta-4 at a glance

Same source tissue, unrelated mechanisms

Thymosin Alpha-1 vs Thymosin Beta-4 comes up as a search precisely because both peptides were isolated from calf thymus extract by Allan Goldstein's laboratory and share a naming convention, not because they do the same job. Ta1 is a 28-amino-acid peptide purified and sequenced in 1977 (Goldstein et al., Proc Natl Acad Sci, 1977). It acts on toll-like receptors 2, 4, and 9 on dendritic cells and other antigen-presenting cells. A 2004 study in Blood traced this to TLR9 specifically: Ta1 primed dendritic cells toward a Th1-biased response, raising interleukin-12 output and shifting T-cell differentiation (Romani et al., Blood, 2004).

Tb4 works through an entirely different physical mechanism. Goldstein's laboratory sequenced it four years after Ta1, in 1981, as a 43-amino-acid protein isolated the same way, from calf thymus extract (Low, Hu, Goldstein, Proc Natl Acad Sci, 1981). It turned out to be the principal actin-sequestering protein in mammalian cells, binding free actin monomers in a 1:1 ratio and maintaining a reserve pool that cells draw on for fast cytoskeletal remodeling during migration, the process keratinocytes rely on to close a wound (Goldstein, Hannappel, Kleinman, Trends Mol Med, 2005). Separately, Tb4 forms a complex with PINCH-1 and integrin-linked kinase that activates Akt, a survival-signaling kinase relevant to cardiomyocytes and wound tissue. TB-500, the 17-amino-acid fragment sold for research under that name, covers only the actin-binding LKKTETQ sequence. Whether it reproduces the ILK-Akt signaling documented for full-length Tb4 has not been tested directly in a published study.

Human trial evidence: immune disease vs dermal repair

The clinical literature for each peptide sits in a different disease area entirely, which is the clearest way to separate the two in practice. Ta1's strongest trial is in chronic hepatitis B. Chien and colleagues at Chang Gung Memorial Hospital in Taiwan randomized 98 patients to a 26-week course, a 52-week course, or an untreated control arm, and found a complete virologic response, meaning clearance of both HBV DNA and HBeAg, in 40.6% of the 26-week group against 9.4% of controls (Chien et al., Hepatology, 1998, n=98).

Sepsis research tells a less favorable story as the trials scaled up. The 2013 ETASS trial randomized 361 ICU patients across several Chinese hospitals to Ta1 or standard care. Twenty-eight-day mortality was 26.0% in the treated group against 35.0% in controls, a relative risk of 0.74 that reached significance only under log-rank testing (P=0.049), not under the primary nonstratified analysis (P=0.062) (Wu et al., Crit Care, 2013, n=361). The follow-up TESTS trial, an adequately powered, double-blind Phase 3 study published in 2025 across 1,106 patients at 22 centers, found no mortality benefit at all: 23.4% mortality with Ta1 against 24.1% with placebo, a hazard ratio of 0.99 (BMJ, 2025, n=1106). A positive signal from a smaller, single-blind trial did not hold up in a properly controlled trial roughly three times its size.

Tb4's clinical program never left dermal and soft tissue repair. A 1999 mouse wound model found that topical or intraperitoneal Tb4 increased reepithelialization by 42% at day 4 and 61% at day 7 compared with saline, and stimulated keratinocyte migration 2 to 3 fold in vitro at concentrations as low as 10 picograms (Malinda et al., J Invest Dermatol, 1999). RegeneRx Biopharmaceuticals then ran Phase 2 trials in patients with pressure ulcers, venous stasis ulcers, and epidermolysis bullosa wounds, reporting faster healing across all three wound types with acceptable tolerability (Treadwell et al., Ann N Y Acad Sci, 2012). No Phase 3 dermal trial has followed as of 2026, and no controlled human trial has tested the TB-500 fragment on its own; every Phase 2 result above is for full-length Tb4.

Neither peptide has a completed Phase 3 trial supporting the use most associated with it in research discussion. Ta1's one Phase 3 trial, in sepsis, was negative. Tb4's wound-healing program has not advanced past Phase 2 in the years since those trials completed.

Pharmacokinetics: two short half-lives from two different studies

Ta1 and Tb4 both clear plasma quickly, though the comparison has to draw on separate studies with different routes of administration. A crossover pharmacokinetic study in nine healthy volunteers found Ta1 reaches peak plasma concentration within 1 to 2 hours after subcutaneous injection, with a terminal half-life under 3 hours across three commercial formulations (Rost et al., Int J Clin Pharmacol Ther, 1999, n=9).

The closest equivalent data for the beta-4 side comes from a 2021 first-in-human Phase 1 study of recombinant Tb4 in 84 healthy Chinese volunteers, using single intravenous doses from 0.05 to 25.0 mcg/kg and, in a separate cohort, daily dosing for 10 days. Terminal half-life ranged from 0.5 to 2.08 hours depending on dose, with no accumulation across the repeated-dose cohort (Wang et al., J Cell Mol Med, 2021, n=84). That trial used full-length recombinant Tb4 given intravenously, not the subcutaneous TB-500 fragment sold to researchers, so the numbers describe the parent protein rather than the exact research compound.

The practical point holds regardless of the gap between studies: each compound clears the body inside a few hours, which is why published research protocols for either one use frequent dosing rather than a single large weekly dose. Anyone converting a study's mcg or mg schedule into a concentration and draw volume for a specific vial size can check the arithmetic with the dosing calculator instead of estimating by eye.

Regulatory status and research handling in Indonesia

The two peptides sit in different regulatory categories outside the research context. Thymalfasin, the synthetic version of Ta1, is marketed as Zadaxin in more than 35 countries for chronic hepatitis B and C, though it has never been approved by the FDA in the United States. Tb4 and TB-500 have no approved drug product anywhere; RegeneRx's Phase 2 program is the furthest any Tb4-derived compound has advanced through clinical development.

Sport regulation draws a sharper line. WADA added thymosin beta-4 and its fragments, including TB-500, to the prohibited list under S2.2 in 2012. Thymosin alpha-1 does not appear on that list, consistent with its role as an approved hepatitis therapy abroad rather than a tissue-repair or performance compound.

Under BPOM's framework for laboratory materials, Ta1 and Tb4 are both handled as research reagents rather than registered pharmaceuticals when supplied to labs in Indonesia. That classification is separate from the clinical thymalfasin product sold as Zadaxin in some Asian markets, a distinction worth keeping straight when reading regulatory summaries that blend the two together. Vials of either compound should go into refrigeration on arrival rather than sit through a humid Bali or Jakarta afternoon at room temperature; the lyophilized peptide storage guide covers the handling window, and the reconstitution guide covers mixing technique once bacteriostatic water is added.

For a full treatment of either compound on its own, see the Thymosin Alpha-1 research overview and the TB-500 and Thymosin Beta-4 research overview. Ta1 and Tb4 are listed together in the thymosin compound catalog, where the shared name prefix causes more confusion than the underlying biology supports.